Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar RXDOC73 (99.19) Submitted: 7/30/2012 6:54:20 AM : Outperform Start Price: $6.09 EXEL Score: -50.88

Potential buy out target from the likes of Pfizer!

Featured Broker Partners


Advertisement